This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
BASF SE (German pronunciation: [beːaːɛsˈʔɛf] ), an initialism of its original name Badische Anilin- & Soda-Fabrik (German for 'Baden Aniline & Soda Factory'), is a German multinational company and the largest chemical producer in the world. Its headquarters is located in Ludwigshafen, Germany. BASF comprises subsidiaries and joint ventures in more than 80 countries, operating six integrated production sites and 390 other production sites across Europe, Asia, Australia, the Americas and Africa. BASF has customers in over 190 countries and supplies products to a wide variety of industries. Despite its size and global presence, BASF has received relatively little public attention since it abandoned the manufacture and sale of BASF-branded consumer electronics products in the 1990s. The company began as a dye manufacturer in 1865. Fritz Haber worked with Carl Bosch, one of its employees, to invent the Haber-Bosch process by 1912, after which the company grew rapidly. In 1925, the company merged with several other German chemical companies to become the chemicals conglomerate IG Farben. IG Farben would go on to play a major role in the economy of Nazi Germany. It extensively employed forced and slave labor during the Nazi period, and produced the notorious Zyklon B chemical used in the Holocaust. IG Farben was disestablished by the Allies in 1945. BASF was reconstituted from the remnants of IG Farben in 1952. It was part of the German economic miracle, and has since expanded considerably. It has received modern criticism for its poor environmental record.
== Clinical significance == Selenium is a vital nutrient in animals, including humans. About 25 different selenocysteine-containing selenoproteins have so far been observed in human cells and tissues. Since lack of selenium deprives the cell of its ability to synthesize selenoproteins, many health effects of low selenium intake are believed to be caused by the lack of one or more specific selenoproteins. Three selenoproteins, TXNRD1 (TR1), TXNRD2 (TR3) and glutathione peroxidase 4 (GPX4), have been shown to be essential in mouse knockout experiments. On the other hand, too much dietary selenium causes toxic effects and can lead to selenium poisoning. The threshold between essential and toxic concentrations of this element is rather narrow with a factor in the range of 10-100. Mutations in Selenoprotein N (SELENON, formerly SEPN1) in humans cause a subtype of congenital muscular dystrophy known as SELENON-related myopathy.
== Obligations and enforcement == The conventions are legally binding, effectively under the Vienna Convention on the Law of Treaties (VCLT). The INCB, charged with monitoring treaty compliance, relies primarily on direct discussion with individual countries to address non-compliance issues. Formal drug treaty disagreements between countries over issues such as treaty compliance and amendment, import-export, jurisdiction, and extradition, are addressed in dispute provisions in each of the conventions that call for remedies including negotiation, mediation, arbitration, judicial proceedings, or other "peaceful means", or turning to the International Court of Justice. Periodically, the UN General Assembly holds special session meetings on drugs that provide a normative framework for the drug conventions. Falling out of compliance with the conventions, apart from denunciation by the UN and other countries, could have practical consequences, particularly for developing nations. The conventions regulate trade in legal pharmaceuticals, including the WHO list of essential drugs—leaving the system could make securing medicine more difficult. Being party to the three conventions is also a requirement for certain trade agreements, and for access to the European Union (EU). Enforcement measures rely largely on dialog and diplomacy. The INCB, in addition to discussion, can call out perceived non-compliance in its reports and in public statements – "naming and shaming" – and by alerting the CND and ECOSOC. Beyond that, it has no practical enforcement power.
Cancer or malignancy Corticosteroid use Current radiotherapy or chemotherapy HIV/AIDS History of organ or bone marrow transplant Immunocompromised persons are twice as likely to die from necrotizing infections compared to the general population, so higher suspicion should be maintained in this group.
Sources: en.wikipedia.org
The only war that can be fought against a superpower is a war of movement. I brought Tariq Aziz all the writings of Che Guevara and Mao Tse Tung on the arts of revolutionary war and he had them translated into Arabic. Fight a war of movement, take the uniforms off, swim among the Iraqi people and whatever their views on the regime, they will undoubtedly provide deep aquifers of support for a patriotic resistance. On 20 March 2003, a coalition including the United Kingdom and United States invaded Ba'athist Iraq. On 28 March 2003, Galloway said in an interview with Abu Dhabi TV:Iraq is fighting for all the Arabs. Why don't the Arabs do something for the Iraqis? Where are the Arab armies? ... They [Tony Blair and George Bush] have lied to the British Air Force and Navy, when they said the battle of Iraq would be very quick and easy. They attacked Iraq like wolves. They attacked civilians. They encountered resistance from Iraqi forces and Iraqi people who are defending their dignity, religion and country ... It is better for Blair and Bush to stop this crime and this catastrophe. ... The best thing British troops can do is to refuse to obey illegal orders. Labour leader Tony Blair said: "His comments were disgraceful and wrong. The National Executive will deal with it".
The classical approach tends to suffer from poor yields as HMF continues to react in aqueous acid, forming levulinic acid. As sugar is not generally soluble in solvents other than water, the development of high-yielding reactions has been slow and difficult; hence while furfural has been produced on a large scale since the 1920s, HMF was not produced on a commercial scale until over 90 years later. The first production plant coming online in 2013. Numerous synthetic technologies have been developed, including the use of ionic liquids, microdroplets, continuous liquid-liquid extraction, reactive distillation, and solid acid catalysts to either remove the HMF before it reacts further or to otherwise promote its formation and inhibit its decomposition.
There are two closely related lep paralogues in Atlantic salmon (Salmo salar). A single lep gene has been documented for green-spotted pufferfish (Tetraodon nigroviridis), rainbow trout (Oncorhynchus mykiss), Arctic charr (Salvelinus alpinus), silver carp (Hypophthalmichthys molitrix), and grass carp (Ctenopharyngodon idellus). In other species there are reports of two closely related lep paralogues, including common carp (Cyprinus carpio) and Atlantic salmon. More distantly related lep genes have been found in medaka (Oryzias latipes) and zebrafish (Danio rerio). At least 2 leptin genes (lepa and lepb) exist in the crown-clade (Fig. 1). Early findings have shown that lepa and lepb share low interspecies aa identity, and are argued to have arisen through whole genome duplication, which occurred early in the teleost lineage. The duplicity of genes has been described for Atlantic salmon, Japanese medaka, common carp and zebrafish. Both lep paralogues cluster with lepa, and therefore suggest that at least one or more form (lepb) may exist in this species, since it is tetraploid. However, previous attempts using genomic synteny have only found the putative genomic duplicates in medaka and zebrafish paralogue. Currently it remains unclear, whether lepb exists in other teleosts due to the degenerative nature of this paralogue.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.